Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran

Nuclear Medicine and Biology

Volumn 30, Issue 3, 2003, Pages 303-315

  Sundberg, Åsa Liljegren ^a   Blomquist, Erik ^a   Carlsson, Jörgen ^a   Steffen, Ann Charlott ^a   Gedda, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dextran; EGF; Radiation dose; Residualizing label; Retention; Tumor targeting

Indexed keywords

CELL RECEPTOR; DEXTRAN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 125; IODINE 131; RADIOISOTOPE;

ARTICLE; CALCULATION; CELL CULTURE; CELL LINE; CELLULAR PARAMETERS; CONJUGATE; DOSE CALCULATION; DRUG DEGRADATION; DRUG RETENTION; DRUG TARGETING; GLIOMA CELL; INCUBATION TIME; ISOTOPE LABELING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RADIATION DOSE; RADIOACTIVITY; RECEPTOR BINDING; TIME; TUMOR CELL;

EID: 0038058806     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00421-3     Document Type: Article

References (47)

1. Bigner S.H., Burger P.C., Wong A.J., Werner M., Hamilton S.R., Muhlbaier L.H., Vogelstein B., Bigner D.D. Gene amplification in malignant human gliomas clinical and histopathological aspects . J. Neuropathol. Exp. Neurol. 47:1998;191-205.
2. Campell I.D., Cooke R.M., Baron M., Harvey T.S., Tappin M.J. The solution structures of epidermal growth factor and transforming growth factor alpha. Prog. Growth. Factor. Res. 1:1989;13-22.
3. Carpenter G., Cohen S. Epidermal growth factor. J. Biol. Chem. 265:1990;7709-7712.
4. Carpenter G. Epidermal growth factor. Ann. Rev. Biochem. 48:1979;193-216.
5. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem. 56:1987;881-914.
6. Chabot J.G., Walker P., Pelletier G. Distribution of epidermal growth factor binding sites in the adult rat liver. Acta Endocrinol. (Copenh.). 113:1986;391-395.
7. Chaffanet M., Chauvin C., Lainé M., Berger F., Chédin M., Rost N., Nissou M.F., Benabid A.L. EGF receptor amplification and expression in human brain tumours. Eur. J. Cancer. 28:1992;11-17.
8. Chandler L.A., Sosnowski B.A., McDonald J.R., Price J.E., Aukerman S.L., Baird A., Pierce G.F., Houston L.L. Targeting tumor cells via EGF receptors selective toxicity of an HBEGF-toxin fusion protein . Int J Cancer. 78:1998;106-111.
9. Christensen M.E. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan. Med. Bull. 45:1998;121-134.
10. Collins V.P. Amplified genes in human gliomas. Cancer Biol. 4:1993;27-32.
11. Foulon C.F., Reist C.J., Bigner D.D., Zalutsky M.R. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 60:2000;4453-4460.
12. Geissler F., Anderson S.K., Venkatesan P., Press O. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells. Cancer Res. 52:1992;2907-2915.
13. Govindan S.V., Mattes M.J., Stein R., McBride B.J., Karacay H., Goldenberg D.M., Hansen H.J., Griffiths G.L. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. Bioconjugate Chem. 10:1999;231-240.
14. Griffiths G.L., Govindan S.V., Sgouros G., Ong G.L., Goldenberg D.M., Mattes M.J. Cytotoxicity with auger electron-emitting radionuclides delivered by antibodies. Int. J. Cancer. 81:1999;985-992.
15. Haigler H.T., Maxfield F.R., Willingham M.C., Pastan I. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J. Biol. Chem. 255:1980;1239-1241.
16. Hartman T., Lundqvist H., Westlin J.E., Carlsson J. Radiation doses to the cell nucleus in single cells and cells in micrometastasis in radionuclide therapy with 131-I labelled ligands or antibodies. Int. J. Radiat. Biol. Phys. 46:2000;1025-1036.
17. Hudson P.J. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:1999;548-557.
18. Hunter W.M., Greenwood F.C. Preparation of Iodine-131 labelled human growth hormone of high specific activity. Nature. 194:1962;495-496.
19. Kohn J., Wilchek M. 1-cyano-4-dimethylamino pyridinium tetrafluoroborate as a cyanylating agent for the covalent attachment of ligand to polysaccharide resins. FEBS Lett. 154:1984;209-210.
20. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res. 5:1999;1539-1549.
21. Kömüves L.G., Feren A., Jones A.L., Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J. Histochem. Cytochem. 48:2000;821-830.
22. Mattes M.J., Shih L.B., Govindan S.V., Sharkey R.M., Ong G.L., Xuan H., Goldenberg D.M. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int. J. Cancer. 71:1977;429-435.
23. Mayer A., Chester K.A., Flynn A.A., Begent R.H.J. Taking engineered anti-CEA antibodies to the clinic. J. Immunol. Meth. 231:1999;261-273.
24. Modjtahedi H., Dean C. The receptor for EGF and its ligands. Expression, prognostic value and target for therapy in cancer (Review). Int. J. Oncol. 4:1994;277-296.
25. Neal D.E., Mellon K. Epidermal growth factor receptor and bladder cancer a review . Urol. Int. 48:1992;365-371.
26. Neal D.E., Sharples L., Smith K., Fennelly J., Hall R.R., Harris A.L. The epidermal growth factor and the prognosis of bladder cancer. Cancer. 65:1990;1619-1625.
27. Olsson P., Black M., Capala J., Coderre J., Hartman T., Makar M., Malmquist J., Pettersson J., Tilly N., Sjöberg S., Carlsson J. Uptake, toxicity and radiation effects of the boron compounds DAAC-1 and DAC-1 in cultured human glioma cells. Int. J. Radiat. Biol. 73:1998;103-112.
28. Olsson P., Lindström A., Carlsson J. Internalization and excretion of epidermal growth factor-dextran associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer. 56:1994;529-537.
29. Ong G.L., Mattes M.J. Limitations in the use of low pH extraction to distinguish internalized from cell surface-bound radiolabeled antibody. Nucl. Med. Biol. 27:2000;571-575.
30. Rainov N.G., Dobberstein K.U., Bahn H., Holzhausen H.J., Lautenschläger C., Heidecke V., Burkert W. Prognostic factors in malignant glioma Influence of the overexpression of oncogene and tumor-suppressor gene products on survival . J. Neuro-Oncol. 35:1997;13-28.
31. 111In-Labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 41:2000;429-438.
32. Reist C.J., Archer G.E., Kurpad S.N., Wikstrand C.J., Vaidyanathan G., Willingham M.C., Moscatello D.K., Wong A.J., Bigner D.D., Zalutsky M.R. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies use of tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts . Cancer Res. 55:1995;4375-4382.
33. Reist C.J., Garg P.K., Alston K.L., Bigner D.D., Zalutsky M.R. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56:1996;4970-4977.
34. Schlegel J., Merdes A., Stumm G., Albert F.K., Forsting M., Hynes N., Kiessling M. Amplification of the Epidermal Growth-Factor-Receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer. 56:1994;72-77.
35. Sorkin A., Waters C.M. Endocytosis of growth factor receptors. BioEssays. 15:1993;375-382.
36. Sorkin A. Endocytosis and intracellular sorting of receptor tyrosine kinases. Frontiers in Bioscience. 3:1998;729-938.
37. Stenerlöw B., Pettersson O.A., Essand M., Blomquist E., Carlsson J. Irregular variations in radiation sensitivity when the linear energy transfer is increased. Radiother. Oncol. 36:1995;133-142.
38. 125I-labeled anti-gp160 monoclonal antibody. Cancer Res. 48:1988;2768-2773.
39. Thorpe S.R., Baynes J.W., Chroneos Z.C. The design and application of residualizing labels for studies of protein catabolism. FASEB. 7:1993;399-405.
40. Tjelle E., Brech A., Juvet L.K., Griffiths G., Berg T. Isolation and characterization of early endosomes, late endosomes and terminal lysosomes their role in protein degradation . J. Cell. Sci. 109:1996;2905-2914.
41. Walker R.A., Dearing S.J. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Treat. 53:1999;167-176.
42. Westermark B., Magnusson A., Heldin C.H. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma. J. Neurosci. Res. 8:1982;491-507.
43. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.
44. Zalutsky M.R., Xu F.J., Yu Y., Foulon C.F., Zhao X.G., Slade S.K., Affleck D.J., Bast R.C. Jr. Radioiodinated antibody targeting of the HER-2/neu oncoprotein effects of labeling method on cellular processing and tissue distribution . Nucl. Med. Biol. 26:1999;781-790.
45. Zhao Q., Carlsson J. In vitro characterization of an end-end coupled mEGF-dextran conjugate using a cultured human glioma cell line. Int. J. Oncol. 11:1997;1263-1269.
46. Zhao Q., Blomquist E., Bolander H., Gedda L., Hartvig P., Jansson J.C., Lundqvist H., Mellstedt H., Nilsson S., Nistér M., Sundin A., Tolmachev V., Westlin J.E., Carlsson J. Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine. Preclinical tests in preparation for clinical trials. Int. J. Mol. Med. 4:1998;693-702.
47. Zhao Q., Tolmachev V., Carlsson J., Lundqvist H., Sundin J., Janson J.C., Sundin A. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjug. Chem. 10:1999;938-946.